Literature DB >> 28028621

Expression of Bruton's tyrosine kinase in B-cell neoplasms evaluated by flow cytometry.

Natália Aydos Marcondes1,2, Flavo Beno Fernandes3, Ana Paula Alegretti4, Gustavo Adolpho Moreira Faulhaber5,3,6.   

Abstract

Bruton's tyrosine kinase (BTK) is a cytoplasmatic protein that is part of the B-cell antigen receptor signaling pathway. Our aim was to evaluate the expression of BTK in B-cell neoplasms and compare it to normal B-cell lymphocytes. After surface staining with CD19 and CD45, flow cytometry staining for intracellular BTK was performed in leukemic or mature B-cells from bone marrow or peripheral blood samples. No differences in BTK expression were identified between groups, or in comparison to control samples, there was no association between BTK expression and the clinical variables evaluated. BTK expression in B-cell neoplasms was similar to that of normal B-cell lymphocytes.

Entities:  

Keywords:  B-cell neoplasm; BTK; Bruton’s tyrosine kinase; Flow cytometry

Mesh:

Substances:

Year:  2016        PMID: 28028621     DOI: 10.1007/s10238-016-0447-9

Source DB:  PubMed          Journal:  Clin Exp Med        ISSN: 1591-8890            Impact factor:   3.984


  19 in total

Review 1.  Targeting the B cell receptor pathway in chronic lymphocytic leukemia.

Authors:  Matthew S Davids; Jennifer R Brown
Journal:  Leuk Lymphoma       Date:  2012-12

Review 2.  Targeting B-cell receptor signaling: changing the paradigm.

Authors:  Nathan Fowler; Eric Davis
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2013

Review 3.  Validation of cell-based fluorescence assays: practice guidelines from the ICSH and ICCS - part II - preanalytical issues.

Authors:  Bruce H Davis; Amar Dasgupta; Steven Kussick; Jin-Yeong Han; Annalee Estrellado
Journal:  Cytometry B Clin Cytom       Date:  2013 Sep-Oct       Impact factor: 3.058

4.  Bruton's tyrosine kinase (Btk) is a useful marker for Hodgkin and B cell non-Hodgkin lymphoma.

Authors:  Iván Fernández-Vega; Luis M Quirós; Jorge Santos-Juanes; María Pane-Foix; Teresa Marafioti
Journal:  Virchows Arch       Date:  2014-11-30       Impact factor: 4.064

Review 5.  The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies.

Authors:  Jan A Burger; John G Gribben
Journal:  Semin Cancer Biol       Date:  2013-09-07       Impact factor: 15.707

6.  The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.

Authors:  Lee A Honigberg; Ashley M Smith; Mint Sirisawad; Erik Verner; David Loury; Betty Chang; Shyr Li; Zhengying Pan; Douglas H Thamm; Richard A Miller; Joseph J Buggy
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-06       Impact factor: 11.205

Review 7.  Bruton's Tyrosine Kinase is involved in innate and adaptive immunity.

Authors:  C Brunner; B Müller; T Wirth
Journal:  Histol Histopathol       Date:  2005-07       Impact factor: 2.303

8.  Deficient expression of Bruton's tyrosine kinase in monocytes from X-linked agammaglobulinemia as evaluated by a flow cytometric analysis and its clinical application to carrier detection.

Authors:  T Futatani; T Miyawaki; S Tsukada; S Hashimoto; T Kunikata; S Arai; M Kurimoto; Y Niida; H Matsuoka; Y Sakiyama; T Iwata; S Tsuchiya; O Tatsuzawa; K Yoshizaki; T Kishimoto
Journal:  Blood       Date:  1998-01-15       Impact factor: 22.113

9.  BTK mutations selectively regulate BTK expression and upregulate monocyte XBP1 mRNA in XLA patients.

Authors:  Marcelo A Teocchi; Vanessa Domingues Ramalho; Beatriz M Abramczuk; Lília D'Souza-Li; Maria Marluce Santos Vilela
Journal:  Immun Inflamm Dis       Date:  2015-06-04

10.  Bruton's tyrosine kinase mediated signaling enhances leukemogenesis in a mouse model for chronic lymphocytic leukemia.

Authors:  Laurens P Kil; Marjolein Jw de Bruijn; Jennifer Ac van Hulst; Anton W Langerak; Saravanan Yuvaraj; Rudi W Hendriks
Journal:  Am J Blood Res       Date:  2013-01-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.